OpenAI has quietly listed a new life‑sciences model, gpt‑rosalind‑discovery, on its API pricing page, pricing it the same as the existing gpt‑rosalind‑research model. The entry appeared on October 10 under a dedicated “Life Sciences Models” section, indicating the company’s…
Continue reading OpenAI Adds gpt‑rosalind‑discovery Model, Signaling New Push Into AI‑Powered Drug DiscoveryKey developments: OpenAI has quietly added a new life‑sciences model, gpt‑rosalind‑discovery, to its API pricing page, positioning it as a dedicated drug‑discovery tool. The model appears beside the existing gpt‑rosalind‑research offering and is priced the same, suggesting a…
Continue reading OpenAI Launches gpt‑rosalind‑discovery as AI Drug Discovery Gains $8.4 B Investment, While Virtual Trial Simulations Boost Pharma Decision‑MakingVirtual‑patient simulations are gaining traction as a way to de‑risk expensive human studies. In July, BioinvestGPT used a simulated trial to predict that the experimental drug del‑desiran would deliver only a modest benefit, a forecast later confirmed by…
Continue reading AI‑Powered Virtual Trials Accelerate Drug Development
